Works matching IS 01676997 AND DT 2021 AND VI 39 AND IP 4

Results: 31

Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1197, doi. 10.1007/s10637-021-01103-8

By:

Pan, Shouhua;
Li, Si;
Xiao, Mingzhe;
Chen, Dongsheng;
Li, Junlong

Publication type:

Article

Correction to: Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy.

Published in:

2021

By:

Pasqualetti, Francesco;
Gonnelli, Alessandra;
Orlandi, Paola;
Palladino, Eleonora;
Giannini, Noemi;
Gadducci, Giovanni;
Mattioni, Roberto;
Montrone, Sabrina;
Calistri, Elisa;
Mazzanti, Chiara Maria;
Franceschi, Sara;
Ortenzi, Valerio;
Scatena, Cristian;
Zavaglia, Katia;
Fanelli, Giuseppe Nicolo;
Morganti, Riccardo;
Santonocito, Orazio;
Bocci, Guido;
Naccarato, Antonio Giuseppe;
Paiar, Fabiola

Publication type:

Correction Notice

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1089, doi. 10.1007/s10637-021-01094-6

By:

Azaro, Analia;
Massard, Christophe;
Tap, William D.;
Cassier, Philippe A.;
Merchan, Jaime;
Italiano, Antoine;
Anderson, Bailey;
Yuen, Eunice;
Yu, Danni;
Oakley III, Gerard;
Benhadji, Karim A.;
Pant, Shubham

Publication type:

Article

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1189, doi. 10.1007/s10637-021-01091-9

By:

Taugner, Julian;
Käsmann, Lukas;
Eze, Chukwuka;
Rühle, Alexander;
Tufman, Amanda;
Reinmuth, Niels;
Duell, Thomas;
Belka, Claus;
Manapov, Farkhad

Publication type:

Article

Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance).

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1072, doi. 10.1007/s10637-021-01090-w

By:

Tran, Nguyen H;
Foster, Nathan R;
Mahipal, Amit;
Byrne, Thomas;
Hubbard, Joleen;
Silva, Alvin;
Mody, Kabir;
Alberts, Steven;
Borad, Mitesh J.

Publication type:

Article

Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 987, doi. 10.1007/s10637-021-01089-3

By:

Ryabaya, Oxana O.;
Abramov, Ivan S.;
Khochenkov, Dmitry A.;
Akasov, Roman;
Sholina, Nataly V.;
Prokofieva, Anastasia A.

Publication type:

Article

A novel methylated analogue of L-Mimosine exerts its therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanoma.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 971, doi. 10.1007/s10637-021-01087-5

By:

Kyriakou, Sotiris;
Cheung, William;
Mantso, Theodora;
Mitsiogianni, Melina;
Anestopoulos, Ioannis;
Veuger, Stephany;
Trafalis, Dimitris T.;
Franco, Rodrigo;
Pappa, Aglaia;
Tetard, David;
Panayiotidis, Mihalis I.

Publication type:

Article

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1081, doi. 10.1007/s10637-021-01086-6

By:

Zauderer, Marjorie G.;
Alley, Evan W.;
Bendell, Johanna;
Capelletto, Enrica;
Bauer, Todd M.;
Callies, Sophie;
Szpurka, Anna M.;
Kang, Suhyun;
Willard, Melinda D.;
Wacheck, Volker;
Varghese, Anna M.

Publication type:

Article

LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1057, doi. 10.1007/s10637-021-01084-8

By:

Dowlati, Afshin;
Harvey, R. Donald;
Carvajal, Richard D.;
Hamid, Omid;
Klempner, Samuel J.;
Kauh, John Sae Wook;
Peterson, Daniel A.;
Yu, Danni;
Chapman, Sonya C.;
Szpurka, Anna M.;
Carlsen, Michelle;
Quinlan, Tonya;
Wesolowski, Robert

Publication type:

Article

Discovery of an orally active antitumor agent that induces apoptosis and suppresses EMT through heat shock protein 90 inhibition.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1179, doi. 10.1007/s10637-021-01083-9

By:

Hu, Yuqiang;
Hao, Ming;
Zhong, Chang;
An, Jun;
Zhang, Yongsheng;
Zhu, Zuobin;
Liu, Bing;
Cheng, Liangjun

Publication type:

Article

Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1132, doi. 10.1007/s10637-021-01082-w

By:

Gao, Antian;
Pan, Xiao;
Yang, Xudong;
Lin, Zitong

Publication type:

Article

First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1047, doi. 10.1007/s10637-021-01081-x

By:

Piha-Paul, Sarina A.;
Thein, Kyaw Z.;
De Souza, Paul;
Kefford, Richard;
Gangadhar, Tara;
Smith, Christopher;
Schuster, Shelly;
Zamboni, William C.;
Dees, Claire E.;
Markman, Ben

Publication type:

Article

Pharmaceutical good manufacturing practice: Leuplin® production in Japan identifies major international shortcomings.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1167, doi. 10.1007/s10637-021-01080-y

By:

Wada, Masahiro;
Ozaki, Akihiko;
Miyachi, Takashi;
Tanimoto, Tetsuya;
Crump, Andy

Publication type:

Article

Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 961, doi. 10.1007/s10637-021-01079-5

By:

Zhao, Linlin;
Lv, Chengfang;
Sun, Lili;
Li, Qi;
Wang, Yuhuang;
Wu, Min;
Wang, Yuying;
Guo, Zhibo;
Bian, Sicheng;
Kong, Desheng;
Lin, Leilei;
Wang, Yu;
Zhou, Jin;
Li, Yinghua

Publication type:

Article

Dissociated response and clinical benefit in patients treated with nivolumab monotherapy.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1170, doi. 10.1007/s10637-021-01077-7

By:

Sato, Yuki;
Morimoto, Takeshi;
Hara, Shigeo;
Nagata, Kazuma;
Hosoya, Kazutaka;
Nakagawa, Atsushi;
Tachikawa, Ryo;
Tomii, Keisuke

Publication type:

Article

Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1106, doi. 10.1007/s10637-021-01076-8

By:

Tamiya, Motohiro;
Tamiya, Akihiro;
Suzuki, Hidekazu;
Taniguchi, Yoshihiko;
Katayama, Kanako;
Minomo, Shojiro;
Nakao, Keiko;
Takeuchi, Naoko;
Matsuda, Yoshinobu;
Naito, Yujiro;
Shiroyama, Takayuki;
Okamoto, Norio;
Okishio, Kyoichi;
Kumagai, Toru;
Atagi, Shinji;
Imamura, Fumio;
Hirashima, Tomonori

Publication type:

Article

Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1159, doi. 10.1007/s10637-021-01075-9

By:

Pasqualetti, Francesco;
Gonnelli, Alessandra;
Orlandi, Paola;
Palladino, Eleonora;
Giannini, Noemi;
Gadducci, Giovanni;
Mattioni, Roberto;
Montrone, Sabrina;
Calistri, Elisa;
Mazzanti, Chiara Maria;
Franceschi, Sara;
Ortenzi, Valerio;
Scatena, Cristian;
Zavaglia, Katia;
Fanelli, Giuseppe Nicolo;
Morganti, Riccardo;
Santonocito, Orazio;
Bocci, Guido;
Naccarato, Giuseppe Antonio;
Paiar, Fabiola

Publication type:

Article

Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1113, doi. 10.1007/s10637-021-01074-w

By:

Alshawa, Anas;
Cadena, Alexandra Perez;
Stephen, Bettzy;
Reddy, Akhila;
Mendoza, Tito R.;
McQuinn, Lacey;
Lawhorn, Kristie;
Zarifa, Abdulrazzak;
Bernhardt, Alexander Maximilian;
Fessaheye, Senait;
Warneke, Carla L.;
Chang, Joe Y.;
Naing, Aung

Publication type:

Article

Autophagy promotes oncolysis of an adenovirus expressing apoptin in human bladder cancer models.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 949, doi. 10.1007/s10637-021-01073-x

By:

Shang, Chao;
Zhu, Yi-Long;
Li, Yi-Quan;
Song, Gao-Jie;
Ge, Chen-Chen;
Lu, Jing;
Xiu, Zhi-Ru;
Li, Wen-Jie;
Li, Shan-Zhi;
Cong, Jia-Nan;
Liu, Zi-Rui;
Li, Xiao;
Sun, Li-Li;
Jin, Ning-Yi

Publication type:

Article

Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 928, doi. 10.1007/s10637-021-01072-y

By:

Chen, Bo;
Sun, Donghong;
Qin, Xiuni;
Gao, Xing-Hua

Publication type:

Article

Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1011, doi. 10.1007/s10637-021-01071-z

By:

Zhu, Yun-ting;
Zhang, Yi-fan;
Jiang, Jin-fang;
Yang, Yong;
Guo, Li-xia;
Bao, Jing-jing;
Zhong, Da-fang

Publication type:

Article

System Xc−: a key regulatory target of ferroptosis in cancer.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1123, doi. 10.1007/s10637-021-01070-0

By:

Liu, Man-ru;
Zhu, Wen-tao;
Pei, Dong-sheng

Publication type:

Article

Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1150, doi. 10.1007/s10637-021-01069-7

By:

Matsuo, Norikazu;
Azuma, Koichi;
Kojima, Takashi;
Ishii, Hidenobu;
Tokito, Takaaki;
Yamada, Kazuhiko;
Hoshino, Tomoaki

Publication type:

Article

AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1139, doi. 10.1007/s10637-021-01066-w

By:

Carlos, Jorge Antonio Elias Godoy;
Lima, Keli;
Costa-Lotufo, Leticia Veras;
Leitão, Andrei;
Machado-Neto, João Agostinho

Publication type:

Article

Identify potential miRNA-mRNA regulatory networks contributing to high-risk neuroblastoma.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 901, doi. 10.1007/s10637-021-01064-y

By:

Shao, Feng-Ling;
Liu, Qing-qing;
Wang, Shan

Publication type:

Article

A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1019, doi. 10.1007/s10637-020-01058-2

By:

Choueiri, Toni K.;
Atkins, Michael B.;
Rose, Tracy L.;
Alter, Robert S.;
Ju, Yawen;
Niland, Katie;
Wang, Yan;
Arbeit, Robert;
Parasuraman, Sudha;
Gan, Lu;
McDermott, David F.

Publication type:

Article

A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1099, doi. 10.1007/s10637-020-01056-4

By:

Danilov, Alexey V.;
Spurgeon, Stephen E.;
Siddiqi, Tanya;
Quinson, Anne-Marie;
Maier, Daniela;
Smith, Dionne;
Brown, Jennifer R.

Publication type:

Article

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1036, doi. 10.1007/s10637-020-01055-5

By:

Yamamoto, Noboru;
Shimizu, Toshio;
Yonemori, Kan;
Kitano, Shigehisa;
Kondo, Shunsuke;
Iwasa, Satoru;
Koyama, Takafumi;
Sudo, Kazuki;
Sato, Jun;
Tamura, Kenji;
Tomomatsu, Junichi;
Ono, Makiko;
Fukuda, Naoki;
Takahashi, Shunji

Publication type:

Article

A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1028, doi. 10.1007/s10637-020-01054-6

By:

Balzarotti, Monica;
Magagnoli, Massimo;
Canales, Miguel Ángel;
Corradini, Paolo;
Grande, Carlos;
Sancho, Juan-Manuel;
Zaja, Francesco;
Quinson, Anne-Marie;
Belsack, Valérie;
Maier, Daniela;
Carlo-Stella, Carmelo

Publication type:

Article

Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1001, doi. 10.1007/s10637-020-01049-3

By:

Chu, Quincy Siu-chung;
Bouganim, Nathaniel;
Fortier, Caroline;
Zaknoen, Sara;
Stille, John R.;
Kremer, Jill D.;
Yuen, Eunice;
Hui, Yu-Hua;
de la Peña, Amparo;
Lithio, Andrew;
Smith, Patricia S.;
Batist, Gerald

Publication type:

Article

A novel ligand of the translationally controlled tumor protein (TCTP) identified by virtual drug screening for cancer differentiation therapy.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 914, doi. 10.1007/s10637-020-01042-w

By:

Fischer, Nicolas;
Seo, Ean-Jeong;
Abdelfatah, Sara;
Fleischer, Edmond;
Klinger, Anette;
Efferth, Thomas

Publication type:

Article